Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia
- PMID: 9633022
- DOI: 10.1007/BF03347285
Parathyroid hormone suppression by 22-oxacalcitriol in the severe parathyroid hyperplasia
Abstract
The suppression of parathyroid hormone (PTH) secretion by the administration of 1,25-dihydroxyvitamin D [1,25(OH)2D3] and 22-oxacalcitriol (OCT) was evaluated in nude mice transplanted with human hyperplastic parathyroid tissue. The parathyroid tissue was obtained for transplantation from a patient with severe secondary hyperparathyroidism who had undergone a parathyroidectomy. Tissue specimens were transplanted into the gluteus muscle of female nude mice. Animals were divided into two groups; one group was fed a normal diet, and the other group was fed a low calcium diet during the administration of OCT and 1,25(OH)2D3. OCT and 1,25(OH)2D3 were intraperitoneally administered two times every week, for a total of eight times. Serum calcium and phosphate levels were significantly higher in the mouse administered 1,25(OH)2D3 than in the mouse administered OCT. Serum alkaline phosphatase activity was elevated similarly in the mouse administered either OCT or 1,25(OH)2D3. OCT strongly suppressed human PTH secretion from the graft in mice with normal serum calcium levels as did 1,25(OH)2D3. However, human PTH secretion from the graft was stimulated by the administration of a low-calcium diet, despite OCT and 1,25(OH)2D3 administration. In summary, OCT and 1,25(OH)2D3 suppress PTH secretion even from severe secondary hyperplastic parathyroid tissue only in mice with normal or high calcium serum levels.
Similar articles
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.J Clin Invest. 1989 Sep;84(3):728-32. doi: 10.1172/JCI114229. J Clin Invest. 1989. PMID: 2760211 Free PMC article.
-
Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1,25-(OH)2D3.J Bone Miner Res. 1992 Jul;7(7):835-9. doi: 10.1002/jbmr.5650070713. J Bone Miner Res. 1992. PMID: 1642151
-
Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.J Clin Invest. 1984 Dec;74(6):2136-43. doi: 10.1172/JCI111639. J Clin Invest. 1984. PMID: 6549016 Free PMC article.
-
The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.Contrib Nephrol. 1991;91:123-8. doi: 10.1159/000420167. Contrib Nephrol. 1991. PMID: 1800003 Review.
Cited by
-
Investigating the effect of testosterone by itself and in combination with letrozole on 1,25-dihydroxy vitamin D and FGF23 in male rats.J Endocrinol Invest. 2019 Jan;42(1):19-25. doi: 10.1007/s40618-018-0875-3. Epub 2018 Mar 20. J Endocrinol Invest. 2019. PMID: 29560610
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources